Europe Hyperphosphatemia Drugs Market 2019-2027

Market OutlookThis research has estimated the Europe hyperphosphatemia drugs market to show an upward trend in terms of revenue and grow rapidly with a CAGR of 16.11% in the forecasting years 2019-2027.France, Italy, the United Kingdom, Germany, Russia, Spain and countries in rest of Europe together form the market for hyperphosphatemia drugs in the European region.The growing aging population and increasing osteoporosis cases in the UK are the major driving factors strengthening the demand for the hyperphosphatemia drugs market in the country. In the UK, around 3 million people are expected to be suffering from osteoporosis. Additionally, more than 230,000 fracture cases are recorded every year due to osteoporosis. A low level of estrogen in women or other hormone might significantly increase the risk of weakening the bones. The increasing aging population in Spain is considered as the major driving factor to strengthen the demand of the hyperphosphatemia drugs market in the country. Spain accounts for a significant proportion of elderly population within Europe. By 2050, one-fourth of Spain’s population is estimated to be over 100 years. The aging population can be considered as the most crucial reason for the rising prevalence of hyperphosphatemia disorders that is driving the growth of the Spain market. In cases of chronic kidney diseases and elderly people, the loss of phosphorus homeostasis due to phosphorus excretion failure causes hyperphosphatemia. And this is growing the demand for the hyperphosphatemia drugs market in the country.Competitive OutlookThe companies contending in the market are Fermenta Biotech, Ltd., Sanofi, Roche Diagnostics Corporation, Pfizer, Inc., Royal DSM N.V., Fresenius Medical Care, Sun Pharmaceutical Industries, Ltd., Cipla, AMAG Pharmaceuticals, Keryx Biopharmaceuticals, Inc., Bio-Tech Pharmacal, Ultragenyx Pharmaceutical, Inc., Johnson and Johnson, Shire, Zeria Pharmaceutical and Bruno Farmaceutici S.p.A.

1. Europe Hyperphosphatemia Drugs Market - Summary

2. Industry Outlook

2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Bargaining Power of Buyers
2.2.3. Bargaining Power of Suppliers
2.2.4. Threat of Substitute Product
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Key Buying Outlook
2.5. Key Insights
2.6. Key Market Trends
2.7. Guidelines Related to the Phosphate Binders
2.8. Market Drivers
2.8.1. Chronic Disorders are Increasing Rapidly
2.8.2. Increase in Public Cognizance
2.8.3. Increase in Geriatric Population
2.9. Market Restraints
2.9.1. Side-Effects Related to the Usage of Hyperphosphatemia Drugs
2.9.2. Strict Food and Drug Administration (Fda) Regulations
2.10. Market Opportunities
2.10.1. Rise in the Aging Population
2.11. Market Challenges
2.11.1. Alternative Dialysis Techniques
2.11.2. Accessibility of Drugs is Limited
2.11.3. Non-Adherence to Treatment Regimes

3. Hyperphosphatemia Drugs Market Outlook - By Dosages

3.1. Solid
3.1.1. Tablet
3.1.2. Powder
3.2. Liquid
3.2.1. Solution

4. Hyperphosphatemia Drugs Market Outlook - By Formulation

4.1.1. Calcium-Based Phosphate Binders
4.1.2. Aluminum-Based Phosphate Binders
4.1.3. Magnesium-Based Phosphate Binders
4.1.4. Iron-Based Phosphate Binders
4.1.5. Other Phosphate Binders

5. Hyperphosphatemia Drugs Market - Regional Outlook

5.1. Europe
5.1.1. Country Analysis
5.1.1.1. United Kingdom
5.1.1.2. France
5.1.1.3. Germany
5.1.1.4. Spain
5.1.1.5. Italy
5.1.1.6. Russia
5.1.1.7. Rest of Europe

6. Competitive Landscape

6.1. Johnson and Johnson
6.2. Zeria Pharmaceutical
6.3. Amag Pharmaceuticals
6.4. Sanofi
6.5. Bruno Farmaceutici S.P.A.
6.6. Roche Diagnostics Corporation
6.7. Royal Dsm N.V.
6.8. Shire
6.9. Cipla
6.10. Ultragenyx Pharmaceutical, Inc.
6.11. Fermenta Biotech, Ltd.
6.12. Biotech Pharmacal
6.13. Sun Pharmaceutical Industries, Ltd.
6.14. Keryx Biopharmaceuticals, Inc.
6.15. Fresenius Medical Care
6.16. Pfizer, Inc.

7. Methodology & Scope

7.1. Research Scope
7.2. Sources of Data
7.3. Research Methodology

Table List

Table 1 Europe Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 2 Phosphorous Levels in Select Foods
Table 3 Europe Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 4 Diagnosis and Clinical Indicators of Chronic Kidney Disease
Table 5 Europe Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)

Figure List

Figure 1 Porter’s Five Forces Model of Hyperphosphatemia Drugs Market
Figure 2 Iron-Based Hyperphosphatemia Drug Approval Status 2014-2017
Figure 3 Rate of Adherence to Phosphate Binders
Figure 4 Europe Hyperphosphatemia Drugs Market in Calcium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 5 Europe Hyperphosphatemia Drugs Market in Aluminum-Based Phosphate Binders 2019-2027 ($ Million)
Figure 6 Europe Hyperphosphatemia Drugs Market in Magnesium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 7 Europe Hyperphosphatemia Drugs Market in Iron-Based Phosphate Binders 2019-2027 ($ Million)
Figure 8 Europe Hyperphosphatemia Drugs Market in Other Phosphate Binders 2019-2027 ($ Million)
Figure 9 Europe Hyperphosphatemia Drugs Market Share 2018 & 2027 (%)
Figure 10 Europe Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 11 United Kingdom Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 12 France Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 13 Germany Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 14 Spain Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 15 Italy Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 16 Russia Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 17 Rest of Europe Hyperphosphatemia Drugs Market 2019-2027 ($ Million)